About the Spore

The Mayo Clinic Breast Cancer SPORE performs breast cancer research that can be quickly applied to clinical practice (translational research). The Breast Cancer SPORE is part of the Women's Cancer Program, a formal research program within the Mayo Clinic Cancer Center.

The Mayo Clinic Breast Cancer SPORE supports four main research projects and three cores and offers research and career development opportunities for junior investigators.

Researchers in the Mayo Clinic Breast Cancer SPORE collaborate with researchers in other breast cancer SPOREs and leading breast cancer programs in the United States through the Translational Breast Cancer Research Consortium. This research consortium was established to aid and expedite the development of sophisticated breast cancer research and its application in clinical practice.

Researchers in the Mayo Clinic Breast Cancer SPORE also collaborate with researchers through the National Institutes of Health's Pharmacogenomics Research Network and with researchers in the Center for Individualized Medicine at Mayo Clinic.

The Breast Cancer SPORE has a long track record of performing practice-changing clinical trials and translational research. James N. Ingle, M.D., founded the breast cancer research program at Mayo Clinic in 1979 and was the principal investigator for the first Mayo Clinic Breast Cancer SPORE grant awarded in 2005.


The Mayo Clinic Breast Cancer SPORE was first funded by the National Cancer Institute (NCI) in 2005. The grant was successfully renewed in 2011 and again in September 2016, when the NCI awarded Mayo Clinic a five-year $12.1 million grant.

A SPORE, or Specialized Program of Research Excellence, is a cornerstone of the NCI's efforts to promote collaborative, interdisciplinary translational cancer research. The Mayo Clinic Cancer Center is one of six cancer research centers with a currently funded NCI SPORE grant for breast cancer research.

Principal investigators

The principal investigators within the Mayo Clinic Breast Cancer SPORE are: